Abstract
s S43 Recipients of larger volumes of MSC (2 and 4 million cells/kg) have shown no improvement in FEV1 but have only 2 months follow at the time of this report (See Figure 2). Conclusion: Preliminary results from this study suggest a beneficial effect on lung function derived from low volume infusion of allogeneic bone-marrow derived MSC. This effect may not occur on recipients of larger volumes of stem cells but longer follow up is needed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
